Volume 27, Issue 30
Research Article

Joint modelling of longitudinal and competing risks data

P. R. Williamson

Corresponding Author

E-mail address: prw@liv.ac.uk

E-mail address: prw@liverpool.ac.uk

Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, Liverpool L69 3GS, U.K.

Director and Professor of Medical Statistics.

Centre for Medical Statistics and Health Evaluation, University of Liverpool, Brownlow Street, Liverpool L69 3GS, U.K.Search for more papers by this author
R. Kolamunnage‐Dona

Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, Liverpool L69 3GS, U.K.

Search for more papers by this author
P. Philipson

School of Mathematics and Statistics, University of Newcastle, Newcastle upon Tyne NE1 7RU, U.K.

Search for more papers by this author
A. G. Marson

Department of Neurological Science, Clinical Sciences Centre for Research and Education, University of Liverpool, Lower Lane, Liverpool L9 7LJ, U.K.

Search for more papers by this author
First published: 29 September 2008
Citations: 40

Abstract

Available methods for joint modelling of longitudinal and survival data typically have only one failure type for the time to event outcome. We extend the methodology to allow for competing risks data. We fit a cause‐specific hazards sub‐model to allow for competing risks, with a separate latent association between longitudinal measurements and each cause of failure.

The method is applied to data from the SANAD trial of anti‐epileptic drugs (AEDs), as a means of investigating the effect of drug titration on the relative effects of lamotrigine (LTG) and carbamazepine (CBZ) on treatment failure. Concern had been expressed that differential titration rates may have been to the disadvantage of CBZ. The beneficial effect of LTG on unacceptable adverse events leading to drug withdrawal did not lessen and indeed increased slightly when a calibrated dose was accounted for in the joint model. Adjustment for the titration rate of LTG relative to CBZ resulted in an unchanged effect of the former on drug withdrawals due to inadequate seizure control. LTG remains the AED of choice from this analysis. Copyright © 2008 John Wiley & Sons, Ltd.

Number of times cited according to CrossRef: 40

  • Faster Monte Carlo estimation of joint models for time-to-event and multivariate longitudinal data, Computational Statistics & Data Analysis, 10.1016/j.csda.2020.107010, (107010), (2020).
  • Competing risks joint models using R-INLA, Statistical Modelling, 10.1177/1471082X19913654, (1471082X1991365), (2020).
  • Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks, Statistical Modelling, 10.1177/1471082X20933363, (1471082X2093336), (2020).
  • Joint modeling of longitudinal and time-to-event data with missing time-varying covariates in targeted therapy of oncology, Communications in Statistics: Case Studies, Data Analysis and Applications, 10.1080/23737484.2020.1782286, (1-23), (2020).
  • An Overview of Joint Modeling of Time-to-Event and Longitudinal Outcomes, Annual Review of Statistics and Its Application, 10.1146/annurev-statistics-030718-105048, 6, 1, (223-240), (2019).
  • The Effect of MSM and CD4+ Count on the Development of Cancer AIDS (AIDS-defining Cancer) and Non-cancer AIDS in the HAART Era, Current HIV Research, 10.2174/1570162X17666181205130532, 16, 4, (288-296), (2019).
  • Review and Comparison of Computational Approaches for Joint Longitudinal and Time‐to‐Event Models, International Statistical Review, 10.1111/insr.12322, 87, 2, (393-418), (2019).
  • Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT, Efficacy and Mechanism Evaluation, 10.3310/eme06060, 6, 6, (1-168), (2019).
  • An issue of identifying longitudinal biomarkers for competing risks data with masked causes of failure considering frailties model, Statistical Methods in Medical Research, 10.1177/0962280219842352, (096228021984235), (2019).
  • TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy, Clinical Infectious Diseases, 10.1093/cid/ciz589, (2019).
  • joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes, BMC Medical Research Methodology, 10.1186/s12874-018-0502-1, 18, 1, (2018).
  • A comparison of joint models for longitudinal and competing risks data, with application to an epilepsy drug randomized controlled trial, Journal of the Royal Statistical Society: Series A (Statistics in Society), 10.1111/rssa.12348, 181, 4, (1105-1123), (2018).
  • Joint Models of Longitudinal and Time-to-Event Data with More Than One Event Time Outcome: A Review, The International Journal of Biostatistics, 10.1515/ijb-2017-0047, 14, 1, (2018).
  • Joint longitudinal and time-to-event models for multilevel hierarchical data, Statistical Methods in Medical Research, 10.1177/0962280218808821, (096228021880882), (2018).
  • Joint Modeling of Multivariate Longitudinal Data and Competing Risks Using Multiphase Sub-models, Statistics in Biosciences, 10.1007/s12561-018-9223-6, (2018).
  • Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes, Statistical Methods in Medical Research, 10.1177/0962280217735560, 28, 3, (717-733), (2017).
  • Accommodating informative dropout and death: a joint modelling approach for longitudinal and semicompeting risks data, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12210, 67, 1, (145-163), (2017).
  • Dynamic Risk Prediction for Cardiovascular Disease: An Illustration Using the ARIC Study, Disease Modelling and Public Health, Part A, 10.1016/bs.host.2017.05.004, (47-65), (2017).
  • Multilevel joint competing risk models, Journal of Physics: Conference Series, 10.1088/1742-6596/890/1/012132, 890, (012132), (2017).
  • Bayesian joint modeling for assessing the progression of chronic kidney disease in children, Statistical Methods in Medical Research, 10.1177/0962280216628560, 27, 1, (298-311), (2016).
  • The use of repeated blood pressure measures for cardiovascular risk prediction: a comparison of statistical models in the ARIC study, Statistics in Medicine, 10.1002/sim.7144, 36, 28, (4514-4528), (2016).
  • Joint Modeling of Repeated Measures and Competing Failure Events in a Study of Chronic Kidney Disease, Statistics in Biosciences, 10.1007/s12561-016-9186-4, 9, 2, (504-524), (2016).
  • Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study, Trials, 10.1186/s13063-016-1342-0, 17, 1, (2016).
  • Associations of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic renovascular disease, Journal of the American Society of Hypertension, 10.1016/j.jash.2015.12.002, 10, 2, (149-158.e3), (2016).
  • Joint latent class model for longitudinal data and interval‐censored semi‐competing events: Application to dementia, Biometrics, 10.1111/biom.12530, 72, 4, (1123-1135), (2016).
  • Time-dependent efficacy of longitudinal biomarker for clinical endpoint, Statistical Methods in Medical Research, 10.1177/0962280216673084, (096228021667308), (2016).
  • Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach, Statistics in Medicine, 10.1002/sim.6731, 35, 3, (382-398), (2015).
  • Joint modelling of repeated measurement and time-to-event data: an introductory tutorial, International Journal of Epidemiology, 10.1093/ije/dyu262, 44, 1, (334-344), (2015).
  • Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy, BMJ Open, 10.1136/bmjopen-2015-009566, 5, 10, (e009566), (2015).
  • A joint frailty model to estimate the recurrence process and the disease‐specific mortality process without needing the cause of death, Statistics in Medicine, 10.1002/sim.6140, 33, 18, (3147-3166), (2014).
  • Identification of Longitudinal Biomarkers in Survival Analysis for Competing Risks Data, Communications in Statistics - Theory and Methods, 10.1080/03610926.2012.716135, 43, 16, (3329-3342), (2014).
  • Identification of longitudinal biomarkers for survival by a score test derived from a joint model of longitudinal and competing risks data, Journal of Applied Statistics, 10.1080/02664763.2014.909789, 41, 10, (2270-2281), (2014).
  • Advances in Joint Modelling: A Review of Recent Developments with Application to the Survival of End Stage Renal Disease Patients, International Statistical Review, 10.1111/insr.12018, 81, 2, (249-269), (2013).
  • Bibliography, Joint Models for Longitudinal and Time-to-Event Data, 10.1201/b12208-12, (239-255), (2012).
  • Flexible parametric joint modelling of longitudinal and survival data, Statistics in Medicine, 10.1002/sim.5644, 31, 30, (4456-4471), (2012).
  • Joint modelling of longitudinal and time‐to‐event data with application to predicting abdominal aortic aneurysm growth and rupture, Biometrical Journal, 10.1002/bimj.201100052, 53, 5, (750-763), (2011).
  • Multivariate and Multistage Survival Data Modeling, Modern Issues and Methods in Biostatistics, 10.1007/978-1-4419-9842-2_6, (145-174), (2011).
  • Variation in Antiepileptic Drug Adherence Among Older Patients with New-Onset Epilepsy, Annals of Pharmacotherapy, 10.1345/aph.1P385, 44, 12, (1896-1904), (2010).
  • Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data, BMC Medical Research Methodology, 10.1186/1471-2288-10-69, 10, 1, (2010).
  • Competing Risk of Death: An Important Consideration in Studies of Older Adults, Journal of the American Geriatrics Society, 10.1111/j.1532-5415.2010.02767.x, 58, 4, (783-787), (2010).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.